Connect with us

Featured

What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!

The opportunity for companies within this sector is massive we are now talking about an industry that is currently worth over US$ 100 billion with the potential in the next 6.5 years to be worth over US$ 200 billion.

StockPrice

Published

on

GT Biopharma (GTBP) an immuno-oncology company focused on innovative treatments for cancer, based on its patent-pending TriKE™ technology has made public a recent study at the University of Minnesota which has confirmed that its HIV-TriKE™ drug platform has successfully killed patient HIV infected cells.


Get Your Free In-Depth Report on GT Biopharma (GTBP)!

Get the Company’s Latest Press Releases Delivered Right to Your Inbox As Well As Other Alerts On Public Companies!


Cancer & HIV/AIDS has a major impact on society in the United States and across the world.

[BREAKING NEWS] GT Biopharma (GTBP) Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells

Cancer.gov estimates that in 2018 1,735,350 new cases of cancer will be diagnosed & 609,640 people will die from the disease in the United States alone!

The World Health Organization estimates that as of 2017 there were 36.7 million people living with HIV globally with 1.8 million people becoming newly infected and 1 million dead of HIV-related causes.

Earlier this year MarketWatch published an article saying:

“The global oncology drugs market was valued at US$ 77.3 billion in 2018, and is projected to exhibit a CAGR of 12.3% during the forecast period (2018 – 2026).”

If these numbers are correct, this means that the global oncology drugs market could Surpass US$ 196.2 Billion by 2026.

According to an article on Fortune Business Insights” the HIV/AIDS drug market was valued at  US$ 25.3 billion in 2018 and according to the website is projected to reach US$ 40.6 billion by the end of 2026 based on a CAGR of 6.1%, between 2019-2026.

Based on this information we are now talking about an industry that is currently worth over US$ 100 billion with the potential in the next 6.5 years to be worth over US$ 200 billion.

This is a Massive Opportunity for Companies In This Space

GT Biopharma (GTBP) is a clinical-stage, immuno-oncology biotech company focused on innovative treatments based on its patent-pending TriKE™ technology. GT Biopharma (GTBP) is in good company within this space. 

Obviously you have the biotech giants:

  • Gilead Sciences, Inc. (NASDAQ:GILD)
  • Incyte Corporation (NASDAQ:INCY)
  • Merck & Co. (NYSE:MRK)

But according to a recent article that was published on The Motley Fool it may be time for investors to give their attention to the “little guys” aka the Small Cap Stocks.

Within this article, The Motley Fool talks about 3 “Out of favor” “Cancer Treatment Stocks.” One of the companies is a small-cap stock that, according to the article, “sports marquee oncology partnerships with Gilead Sciences, Incyte, as well as Merck.” 

This is a great example of a small-cap company utilizing its relationships with credible, larger entities to forward their corporate missions.

Connecting The Dots

Similarly, when investors look at GT Biopharma (GTBP) they will notice that the company is indeed a small-cap stock and like the company The Motley Fool mentioned, has ties to a large entity to help further its own corporate missions.

GT Biopharma (GTBP) has deep ties to the University of Minnesota & its prestigious Masonic Cancer Center, a comprehensive cancer center designated by the National Cancer Institute. 

The University of Minnesota is the site for the current in-human TriKE™ phase 1 clinical trial. 

In addition to being the host site for GT Biopharma (GTBP) ’s in-human clinical trial Deputy Director of the University of Minnesota’s Masonic Comprehensive Cancer Center. Dr. Jeffery Miller was hired to be GT Biopharma (GTBP) ’s Consulting Chief Medical Officer in August 2019.

To top it off on September 19, 2019, it was announced on the University of Minnesota’s website that:

University of Minnesota discovery is now a first-in-human clinical trial for leukemia & designer molecule will activate the patient’s own immune cells to attack cancer. The discovery of tri-specific natural killer engagers (TriKE™), a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially, has led to a new Phase I, first-in-human study to treat leukemia. The study is opening exclusively at the University of Minnesota Medical Center and is being sponsored by GT Biopharma, Inc.

The relationship that GT Biopharma (GTBP) builds with the University of Minnesota and its Consulting Chief Medical Officer Dr. Jeffrey Miller continues to be a fruitful one.

On October 3, 2019 GT Biopharma (GTBP) announced that Tim Schacker, M.D., Jeffrey S. Miller, M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg discussing their design of an HIV-TriKE™ containing an antigen-binding fragment (Fab) from a broadly-neutralizing antibody targeting the HIV-Env protein. The HIV-TriKE™ is designed to target HIV while redirecting NK cell killing specifically to actively replicating HIV infected cells.

Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma, commented, “We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease, and is able to kill HIV in the reservoir.”  Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy.”


Get Your Free In-Depth Report on GT Biopharma (GTBP)!

Get the Company’s Latest Press Releases Delivered Right to Your Inbox As Well As Other Alerts On Public Companies!


How Does GT Biopharma (GTBP) Measure Up Against the Competition?

GT Biopharma (GTBP) Is Developing Treatments That Stand Head-To-Head With Some Of The Industry’s Top Companies

A unique opportunity could be presenting itself for GT Biopharma (GTBP) to far surpass some of the industry’s biggest companies. 

The key to this opportunity is within the use of NK cells versus the standard “T-Cell” treatment methods.

Lose You?
Don’t Worry We’ll Explain Further…

Amgen (AMGN) – $175 Million Revenue Potential

Amgen’s T-cell cell engager was approved for marketing in December 2014. Under the branded treatment, Blincyto, Amgen’s treatment targets patients with specific types of leukemia. Where this treatment is based on T-cell therapy, it needs to activate the body’s immune system first, which could present its own list of risks. In comparison, GT BIopharma’s TriKEs/TetraKEs engage NK cells which may have potential advantages as there’s no need to “prime” the immune system. The bottom line is that even in this case, the more archaic T-cell treatment helped generate $175 million in sales in 2017 for Amgen’s Blincyto.

Gilead (GILD) And Its Acquisition of Kite Pharma – Buyout Valued At $11.9 Billion

In October 2017, Kite Pharma’s (previously publicly traded as “KITE”) therapy, Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with certain types of lymphoma after two or more lines of systemic therapy. Based on this development, one of the mega-industry leaders, Gilead (GILD) bought out the company for a cool $11.9 Billion. As with the Amgen case, GT Biopharma (GTBP) NK cell platform poses even more opportunity beyond the simple T-Cell or “CAR-T” cell treatment as targeted therapies begin to take a more prominent place in cancer and immuno-oncology treatment.

Affimed (AFMD) & Roche (RHHBY) Collaboration Through Genentech – $5.9 Billion Deal

Clinical stage biopharmaceutical company Affimed (AFMD) inked a deal with a potential value of nearly $6 billion with Roche (RHHBY) company, Genentech. This is one of the clearest examples of the potential of NK cell platforms. Because these “engager-based” immunotherapeutics can treat multiple cancers, the therapies can be tailor-made for patients without having to “pre-stimulate” the body’s immune system. Not only did Affimed get an upfront payment of $96 million but with milestones, it can receive up to another $5 billion.

Meet The GT Biopharma (GTBP) Management Team

GT Biopharma (GTBP) has a management team comprised of the biotech sector’s biggest, brightest and most successful.

ANTHONY J. CATALDO

Chairman, Chief Executive Officer & President


Mr. Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in July of 2014, where he changed the Company’s profile with the inclusion of oncology assets. From February 2011 to June 2013 Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, Inc., now known as Iovance Biotherapeutics, Inc., (IOVA). Mr. Cataldo created the highly successful IOVA/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: Calypte Biomedical Corporation, and Senetek, PLC.

JEFFREY S. MILLER, M.D.

Consulting Chief Medical Officer


Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Dr. Miller is currently a Professor of Medicine at the University of Minnesota. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. He has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants.

STEVEN WELDON

Chief Financial Officer & Director


Mr. Weldon has extensive experience with GT Biopharma (GTBP) having served on the Board of Directors from September 2014 through October 2018. He also served as Chief Financial Officer of GT Biopharma (GTBP) from November 2014 through October 2018. Mr. Weldon has over 16 years of financial and accounting experience. Mr. Weldon’s financial background includes experience in managerial, private accounting and planning. He has served on the board of several publicly traded companies as both, chief executive officer and chief financial officer. For several years, he taught accounting and tax courses to undergrad students at Florida Southern College. He received his bachelor of science degree and his Master’s in Business Administration from Florida Southern College and is a licensed Certified Public Accountant in the State of Florida.

How Does GT Biopharma (GTBP) Measure Up Against the Competition?

  1. GT Biopharma (GTBP) is operating within a space that is currently valued at US$ 100 billion and is estimated to be valued at US$ 200 billion by 2026. This is a massive growth opportunity.
  2. GT Biopharma (GTBP) has made public a recent study at the University of Minnesota which has confirmed that its HIV-TriKE™ drug platform has successfully killed patient HIV infected cells.
  3. GT Biopharma’s (GTBP) deep ties with the University of Minnesota & its Masonic Cancer Center, its Deputy Director & now GT Biopharma’s (GTBP) Consulting Chief Medical Officer Dr. Jeffery Miller give the company a huge advantage.
  4. GT Biopharma (GTBP) is developing treatments that stand head-to-head with some of the industry’s top companies.
  5. GT Biopharma (GTBP) has a management team comprised of some of the biggest, brightest and most successful professionals within the biotech sector.

Get Your Free In-Depth Report on GT Biopharma (GTBP)!

Get the Company’s Latest Press Releases Delivered Right to Your Inbox As Well As Other Alerts On Public Companies!


Sources

https://www.marketwatch.com/press-release/global-oncology-drugs-market-to-surpass-us-1962-billion-by-2026-2019-01-30

https://www.fortunebusinessinsights.com/industry-reports/hiv-aids-drugs-market-101115

https://www.cancer.gov/about-cancer/understanding/statistics

https://www.who.int/features/qa/71/en/

https://www.fool.com/investing/2019/10/10/3-cancer-treatment-stocks-to-buy-right-now.aspx

https://www.gtbiopharma.com/news-media/press-releases/detail/173/gt-biopharma-hires-chief-medical-officer-jeffery-miller

https://www.cancer.umn.edu/node/17706https://finance.yahoo.com/quote/GTBP?p=GTBP&.tsrc=fin-srch


Disclaimer:

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading
Click to comment

Featured

Stock Price Newsletter – November 22, 2019

Joe Samuel

Published

on

stock price newsletter

Active Biotech Stocks To Watch As Markets Flirt With New Highs

Biotech stocks are often regarded as safe due to the simple fact that it is a sector that has grown across the board for quite some time. However, in addition, the biotech sector has the potential to generate handsome gains if an investor ends up choosing the right stock.

Click Here To Read More


Streaming Stocks Take Aim At Winning The Content War

The emergence of competition for streaming services from other corporate giants like Disney has started to raise eyebrows. It has been projected that the industry is going to be worth $124.57 billion by 2025. That being said, there may be ample opportunity for investors. Here is a look at a few tech stocks to watch that could be set to prove themselves on this new battlefield.

See For Yourself


Defense Stocks in Focus This Week

It is a well-known fact that the United States has the biggest defense budget in the world and the budget rises every year. That’s is why defense stocks are almost always in demand. These are companies that often win mega contracts from the American government and are immune from the volatile swings of the market.

Continue Reading

Continue Reading

Biotechnology

Active Biotech Stocks To Watch As Markets Flirt With New Highs

A. Lawrence

Published

on

biotech stocks to watch

Biotech stocks is often regarded as safe due to the simple fact that it is a sector that has grown across the board for quite some time. However, in addition, the biotech sector has the potential to generate handsome gains if an investor ends up choosing the right stock.

Investors need to watch the market closely and be aware of the latest news from the sector in order to make the best choices. Here is a look at 3 biotech stocks that turned heads in the biotech sector this week.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech (PMCB) is in the prep phase of clinical trials and readying to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.

“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”

As one report puts it, “Clinical trials are essential for the development of new treatments, and PharmaCyte will enter this upcoming trial with two essential goals in mind—the future of its pancreatic cancer treatment and the future of its technology.”

For more on PharmaCyte, Click Here

VIVUS (VVUS)

The first biotech stock to consider here is that of VIVUS, Inc. (NASDAQ:VVUS), which has rallied on Wednesday on the back of a major announcement from the company. The stock rallied by 3% this morning in premarket trade after the results were announced from the Phase 1 clinical trial of its product Qsymia. The medicine in question is a capsule and is meant for people who suffer from binge eating disorder.

It should be noted that medicine is currently approved in the United States when used by people in order to reduce calories in their diets. It is a major development for VIVUS and it is no surprise that the stock rallied today.

Diffusion Pharmaceuticals (DFFN)

The other biotech stock that is worth including in the watch list is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), which made solid gains yesterday on the back of the announcement of positive preliminary data from the Phase 3 clinical trial of Trans Sodium Crocetinate (TSC). The medicine is meant for treating inoperable glioblastoma and in the results, it has been revealed that patients recorded a median survival duration of as long as 14.3 months.

Historically, the standard survival duration is only 9.2 months. The results triggered a rally in the stock and the Diffusion stock soared by as much as 67.60%.

list of healthcare stocks to watch

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Featured

Defense Stocks in Focus This Week

Joe Samuel

Published

on

defense stocks to watch weapons detection

While Many Watch Marijuana Stocks, Defense Gets Another Push

It is a well-known fact that the United States has the biggest defense budget in the world and the budget rises every year. That’s is why defense stocks are almost always in demand. These are companies that often win mega contracts from the American government and are immune from the volatile swings of the market.

Even if the economic situation is weak, the government will continue to spend on defense. Therefore these stocks are so attractive for investors. Here is a look at three penny stocks that are worth tracking at this point in time.

Liberty Defense Holdings (SCAN.V) (LDDFF)

There have been more mass shootings this year in the United States than there have been days in the year. Over 330 mass shootings [1], to be exact. This is becoming a huge issue that is costing precious lives and could see billions of dollars spent to fix this situation.

Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) plans to address this issue using HEXWAVE, a next-generation high-tech security scanning system. It will use advanced, low-power radar, 3D-imaging, and Artificial Intelligence (AI) to screen people at public gatherings such as sports games, unobtrusively. The company itself has been making paramount progress this quarter.

Most recently the company signed a collaboration agreement with Port Tampa Bay to beta test HEXWAVE. Between the years 2007 and 2017, total cruise ship passenger capacity grew by 25 percent in North America, with the following 10 years estimated to see a further 41 percent increase, according to a 2017 report. So this move could prove to be well-timed for a company like Liberty Defense (TSX: SCAN.V) (OTC: LDDFF).

Also, keep in mind that they’ve also got agreements in place with FC Bayern Munich’s Allianz Arena in Germany, Rogers Arena in Vancouver, British Columbia, Maryland Stadium Authority’s Camden Yards Complex, and in the state of Utah. There’s also projects with the Virginia Division of Capitol Police, in Sleiman shopping centers, in a Hindu temple, in the Metro Toronto Convention Centre, in Toronto Pearson International Airport, and with the University of Wisconsin Police Department. To say that they’ve laid the groundwork may be an understatement and results of these beta tests are highly anticipated by the company.

Air Industries Group (AIRI)

The first defense stock to consider is that of Air Industries Group Inc (NYSEAMERICAN:AIRI). The company is involved in aerospace and defense space. Air is best known for manufacturing, designing and selling products that are meant for flight safety. The Air stock has done particularly well this year and has soared by as much as 65% thus far. It is important to point out that Air counts some of the biggest names in the industry among its clients.

Products made by the company are currently used in Sikorsky’s UH-60 Black Hawk, Lockheed Martin’s F-35 Joint Strike Fighter, Northrop Grumman’s E2 Hawkeye, Boeing’s 777, Airbus’ 380 commercial airliners, and the US Navy F-18 and USAF F-16 fighter aircraft. It also supplies equipment for different United States State Department Branches. It goes without saying that this is a stock that should be tracked closely.

Astrotech Corp (ASTC)

The other defense stock that should be in investors’ watch lists is that of Astrotech Corp (NASDAQ:ASTC). On November 14, it emerged that a product made by the company’s subsidiary 1st Detect has been chosen to conduct live screening at Miami International Airport by the U.S.

Department of Homeland Security (DHS) Transportation Security Administration (TSA). The product in question is TRACER 1000 and ever since the announcement was made, there has been an impressive rally in the Astrotech stock. That stock rallied by as much as 80% in one day.

weapons detection stocks security stocks

Disclaimer:Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid $75,000 (CASH) by Liberty Defense Holdings AND HAVE EXTENDED coverage for a period from 11/1/2019 – 11/30/2019. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. For previous compensation see our FULL DISCLAIMER HERE.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com

Enter Your Email Address & Name Below to Receive Your Free Report on (GTBP)

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com